T-piece复苏器在产房中对早产儿复苏中的应用效果评价*

目的:探讨T-piece复苏器在产房中对早产儿复苏中的应用效果。方法:选择2011年1月至2016年12月在本院产科出生的早产儿(胎龄28～37周)62例,随机分为对照组与观察组,各31例,对照组患儿给予自动充气式复苏囊正压人工通气,观察组患儿给予T组合复苏器正压人工通气,比较两组患儿1、5、10 min Apgar评分、肺气漏发生率,以及缺氧缺血性脑病、支气管肺发育不良、坏死性小肠结肠炎、动脉导管未闭、高胆红素血症率。结果:两组患儿胎龄、性别、分娩方式、出生体重、出生后1、5、10 min Apgar评分等方面差异均无统计学意义(P0.05)。与对照组相比,观察组气漏发生率降低,差异有统计学意义(P0.05)。两组患儿缺氧缺血性脑病、支气管肺发育不良、坏死性小肠结肠炎、动脉导管未闭、高胆红素血症率差异无统计学意义(P0.05)。结论:T-piece复苏器在产房中早产儿窒息复苏中的应用效果显著,具有操作简单、效率高等优点,两组复苏成功率差别不大,但T-piece复苏器能可有效减少肺气漏的发生,进而降低新生儿的病死率。     

细胞增殖寿命的延长研究进展

细胞具有增殖能力的关键是能顺利通过细胞周期的各个控制点。在体外培养的条件下,细胞会因生长环境的不适宜而触发     

mTOR信号通路与调节

哺乳动物雷帕霉素靶蛋白mTOR是一种非典型丝氨酸／苏氨酸蛋白激酶,可整合细胞外信号,磷酸化下游靶蛋白核糖体p70S6激酶,如S6K1及4E—BP1,影响转录与翻译,从而参与调控细胞生长、增殖等过程。近年来研究发现,调控mTOR通路可以干预某些疾病的病理过程。mTOR研究的新发现,可望为今后相关疾病的治疗提供新的靶点。     

三种中药制剂Ams-11、Fw-13、Tul-17逆转肿瘤细胞多药耐药性的研究

为寻找能有效逆转肿瘤细胞多药耐药性的药物,通过体外细胞实验对Ams-11、Fw-13、Tul-17三种中药制剂逆转肿瘤细胞多药耐药性的作用进行了分析。并用流式细胞仪测定了Tul-17处理细胞后药物累积程度的变化及细胞P糖蛋白表达情况。为进一步研究体外细胞实验筛选出的多药耐药逆转剂在体内的药效学,将其中Fw13用于人白血病K562/ADR裸鼠移植瘤逆转试验。结果:在无细胞毒性的剂量范围内,该三种中药制剂均能明显增强多药耐药细胞对抗癌药物的敏感性,而且其逆转作用呈剂量依赖关系。Tu-17处理后,K562耐药细胞表达的P糖蛋白较对照降低1.5倍,对罗丹明123的累积量是对照的2.5倍。用Fw13治疗人白血病K562/ADR裸鼠移植瘤,可将硫酸长春新碱(VCR)对K562/ADR的抑瘤率从19.79%提高到86.59%,与单独VCR治疗疗效有显著性差异(P<0.05)。结果表明,这三种中药制剂可望成为肿瘤多药耐药逆转剂,在肿瘤化疗中发挥作用。     

Inhibition of telomerase in tumor cells by ribozyme targeting telomerase RNA component

Telomerase plays an important role in cell proliferation and carcinogenesis and is believed to be a good target for anti-cancer drugs. Elimination of template function of telomerase RNA may repress the telomerase activity. A hammer-headed ribozyme (telomerase ribozyme, te-loRZ) directed against the RNA component of human telomerase (hTR) was designed and synthesized. TeloRZ showed a specific cleavage activity against the hTR. The cleavage efficacy reached 60%. A eukaryotic expression plasmid containing teloRZ gene was inducted into HeLa cells by lipofectamine, the telomerase activity in HeLa cells expressing teloRZ decreased to one eighth of that in the control cells. The doubling time increased significantly and the apoptosis ratio was elevated with increasing population doublings (PDS). After 19-20 PDS 95% cells were apoptotic. To further investigate the effect of teloRZ on tumor growth, the eukaryotic expression plasmid containing teloRZ was injected into transplanted tumor of nude mouse. The teloRZ e     

褪黑素与缺血再灌注损伤

褪黑素(melatonin,MT)具有强效抗氧化作用,在肠、肝脏、心脏、脑等器官的缺血再灌注损伤实验中具有清除自由基、保护线粒体、抗细胞凋亡等保护性作用。本文综合褪黑素应用于缺血再灌注损伤的动物实验的近几年相关文献,总结并分析褪黑素在缺血再灌注损伤动物实验中的保护作用及其相关机制。     

端粒酶的非端粒保护作用

端粒酶与细胞永生化和肿瘤的发生发展密切相关,过去认为是由于端粒酶保护端粒从而阻止因端粒缩短所导致的细胞凋亡;然而近年来,越来越多证据表明:端粒酶在维持端粒长度之外,还存在着非端粒保护作用。通过对其非端粒保护作用的研究,有助于深入而全面地阐明端粒酶的生物学行为及其作用机理,对于肿瘤等疾病的治疗具有重要意义。本文对端粒酶的非端粒保护作用进行小结。     

Ribozyme抑制端粒酶活性的肿瘤基因治疗

针对端粒酶RNA组分模板区设计合成锤头状端粒酶核酶(teloRZ),构建了teloRZ基因体外转录质粒P^SPT19-teloRZ和真核表达质粒P^{XJ-neo-teloRZ}.用T₇/SP₆体外转录系统检测了teloRZ对端粒酶RNA组分的体外切割效率,达60%左右.用脂质体介导法, 将P^{XJ-neo-teloRZ}导入HeLa细胞和裸鼠移植瘤,结果使HeLa细胞端粒酶活性降至对照细胞的11%～12.5%, 细胞生长速度明显变慢,传至19～20代时出现95%凋亡.裸鼠移植瘤注射P^{XJ-neo-teloRZ} 14 d后,端粒酶活性下降69%,抑瘤率达62%.实验表明,该核酶可望成为有效的端粒酶抑制剂,在肿瘤治疗中发挥作用.     

基质细胞衍生因子-1及其受体CXCR4与肿瘤的生物学行为

基质细胞衍生因子-1(stromal cell derived factor-1, SDF-1)是由基质细胞持续产生并分布广泛的趋化因子,CXCR4则为SDF-1的高度特异性受体.最近研究显示,SDF-1/CXCR4生物轴除了调节肿瘤的侵袭转移能力外,还与多种肿瘤的生物学行为关系密切.本文主要介绍SDF-1/CXCR4的结构与功能、SDF-1/CXCR4与肿痛生物学行为的关系,探讨以SDF-1/CXCR4生物轴为靶点的肿瘤治疗前景.     

Inhibition of telomerase in tumor cells by ribozyme targeting telomerase RNA component

Telomerase plays an important role in cell proliferation and carcinogenesis and is believed to be a good target for anti-cancer drugs. Elimination of template function of telomerase RNA may repress the telomerase activity. A hammer-headed ribozyme (telomerase ribozyme, teloRZ) directed against the RNA component of human telomerase (hTR) was designed and synthesized. TeloRZ showed a specific cleavage activity against the hTR. The cleavage efficacy reached 60%. A eukaryotic expression plasmid containing teloRZ gene was inducted into HeLa cells by lipofectamine, the telomerase activity in HeLa cells expressing teloRZ decreased to one eighth of that in the control cells. The doubling time increased significantly and the apoptosis ratio was elevated with increasing population doublings (PDS). After 19–20 PDS 95% cells were apoptotic. To further investigate the effect of teloRZ on tumor growth, the eukaryotic expression plasmid containing teloRZ was injected into transplanted tumor of nude mouse. The teloRZ effectively inhibited the telomerase activity in transplanted tumor, promoted apoptosis of the transplanted tumor cells, and decreased the tumor size significantly. These results indicate that teloRZ can effectively inhibit telomerase activity and growth of tumor cells, and suggest the potential use of this ribozyme in anti-cancer therapy.